HC Wainwright & Co. Reiterates Buy on Protalix BioTherapeutics, Maintains $12 Price Target
3/19/2026
Impact: 70
Healthcare
HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Protalix BioTherapeutics (AMEX: PLX) and maintained a price target of $12 for the stock.
AI summary, not financial advice
Share: